Published in Vaccine on September 01, 1996
DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol (1998) 1.57
Herpes simplex virus type 2 vaccines: new ground for optimism? Clin Diagn Lab Immunol (2004) 0.94
Gene therapy for infectious diseases. Clin Microbiol Rev (1998) 0.91
Development of DNA vaccines against hemolytic-uremic syndrome in a murine model. Infect Immun (2003) 0.90
Immunization of the female genital tract with a DNA-based vaccine. Infect Immun (1998) 0.90
Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. J Gen Virol (2012) 0.89
Vaginal memory T cells induced by intranasal vaccination are critical for protective T cell recruitment and prevention of genital HSV-2 disease. J Virol (2014) 0.88
A mucosal vaccination approach for herpes simplex virus type 2. Vaccine (2010) 0.87
Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice. J Virol (2011) 0.86
High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection. J Invest Dermatol (2008) 0.85
Use of amplicon-6 vectors derived from human herpesvirus 6 for efficient expression of membrane-associated and -secreted proteins in T cells. J Virol (2004) 0.85
Estradiol improves genital herpes vaccine efficacy in mice. Vaccine (2009) 0.85
The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice. J Virol (2004) 0.84
Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases. Clin Exp Metastasis (2002) 0.81
Gene gun-mediated DNA immunization primes development of mucosal immunity against bovine herpesvirus 1 in cattle. J Virol (2000) 0.77
Prospects and perspectives for development of a vaccine against herpes simplex virus infections. Expert Rev Vaccines (2014) 0.76
Control of STDs--the role of prophylactic vaccines against herpes simplex virus. Sex Transm Infect (1998) 0.75
Differential expression of mRNA and miRNA in guinea pigs following infection with HSV2v. Exp Ther Med (2017) 0.75
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med (1998) 6.75
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr (2000) 3.53
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis (2000) 2.90
Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology (1997) 2.37
T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol (1998) 2.31
Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol (2005) 2.28
Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis (1989) 2.21
Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J Infect Dis (1982) 2.16
Serologic analysis of first-episode nonprimary genital herpes simplex virus infection. Presence of type 2 antibody in acute serum samples. Am J Med (1984) 2.05
Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2. Virology (1995) 1.86
Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics (1996) 1.77
Translational inhibition mediated by a short upstream open reading frame in the human cytomegalovirus gpUL4 (gp48) transcript. J Virol (1993) 1.68
Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis (1987) 1.68
Human rotavirus studies in volunteers: determination of infectious dose and serological response to infection. J Infect Dis (1986) 1.68
Expression of the herpes simplex virus type 2 latency-associated transcript enhances spontaneous reactivation of genital herpes in latently infected guinea pigs. J Exp Med (1995) 1.63
Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob Agents Chemother (2003) 1.59
Allergic reactions to workplace allergens. JAMA (1997) 1.57
The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection. Sex Transm Infect (2006) 1.56
Molecular cloning of the guinea pig cytomegalovirus (GPCMV) genome as an infectious bacterial artificial chromosome (BAC) in Escherichia coli. Mol Genet Metab (2001) 1.53
Evaluation of a possible association of urban air toxics and asthma. Environ Health Perspect (1995) 1.52
Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob Agents Chemother (2000) 1.49
Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy (1999) 1.45
Evaluation of occupational asthma from airborne egg protein exposure in multiple settings. Chest (1990) 1.45
The characteristic site-specific reactivation phenotypes of HSV-1 and HSV-2 depend upon the latency-associated transcript region. J Exp Med (1996) 1.41
House dust (1-3)-beta-D-glucan and wheezing in infants. Allergy (2007) 1.40
More rapid isolation of herpes simplex virus in a continuous line of mink lung cells than in Vero or human fibroblast cells. Diagn Microbiol Infect Dis (1984) 1.39
Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract. Virology (1995) 1.36
The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model. J Infect Dis (1999) 1.32
Pulmonary and immunologic evaluation of foundry workers exposed to methylene diphenyldiisocyanate (MDI). J Allergy Clin Immunol (1988) 1.29
Mediastinal and supraclavicular lymphadenitis and pneumonitis due to Chlamydia trachomatis serovars L1 and L2. N Engl J Med (1984) 1.25
Acceptability of human papillomavirus self testing in female adolescents. Sex Transm Infect (2005) 1.24
Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology (1997) 1.23
Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J Infect Dis (2001) 1.23
Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents. Clin Infect Dis (1997) 1.22
Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis (1993) 1.21
Recurrent genital herpes simplex virus infection in guinea pigs. Intervirology (1985) 1.20
Clinical and pharmacokinetic evaluation of nafcillin in infants and children. J Pediatr (1978) 1.20
HSV shedding. Antiviral Res (2004) 1.18
Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis (1998) 1.18
A combined respiratory and cutaneous hypersensitivity syndrome induced by work exposure to quaternary amines. J Allergy Clin Immunol (1994) 1.17
Immune protection against HSV-2 in B-cell-deficient mice. Virology (2000) 1.17
Varicella-zoster virus infection of strain 2 guinea pigs. J Infect Dis (1985) 1.16
Herpes simplex virus vaccines. Vaccine (1999) 1.14
Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc (1999) 1.14
Poly(sodium 4-styrene sulfonate): an effective candidate topical antimicrobial for the prevention of sexually transmitted diseases. J Infect Dis (2000) 1.14
Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob Agents Chemother (1994) 1.14
Plant products as topical microbicide candidates: assessment of in vitro and in vivo activity against herpes simplex virus type 2. Antiviral Res (1999) 1.13
The effects of acyclovir on antibody response to herpes simplex virus in primary genital herpetic infections. J Infect Dis (1984) 1.13
Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J Infect Dis (1995) 1.13
The natural history of adult asthma: what do we know? Ann Allergy Asthma Immunol (2000) 1.10
Zosteriform spread of herpes simplex virus type 2 genital infection in the guinea-pig. J Gen Virol (1986) 1.09
Rubella immunity in older children, teenagers, and young adults: a comparison of immunity in those previously immunized with those unimmunized. J Pediatr (1982) 1.09
Protection against rotavirus disease after natural rotavirus infection. US Rotavirus Vaccine Efficacy Group. J Infect Dis (1994) 1.08
Topical microbicides. Current status and research considerations for adolescent girls. Sex Transm Dis (1998) 1.08
Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res (1988) 1.07
Antibody response, recurrence patterns and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea-pigs: effects of acyclovir. J Gen Virol (1986) 1.06
Detection of IgE-mediated respiratory sensitization in workers exposed to hexahydrophthalic anhydride. J Allergy Clin Immunol (1985) 1.05
Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res (1989) 1.04
Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months. Pediatrics (1982) 1.03
Indirect assessment of 4,4'-diphenylmethane diisocyanate (MDI) exposure by evaluation of specific humoral immune responses to MDI conjugated to human serum albumin. Am J Ind Med (1998) 1.01
Immune responses in farm workers after exposure to Bacillus thuringiensis pesticides. Environ Health Perspect (1999) 1.01
Poly(sodium 4-styrene sulfonate): evaluation of a topical microbicide gel against herpes simplex virus type 2 and Chlamydia trachomatis infections in mice. Clin Microbiol Infect (2003) 1.00
DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis (1996) 1.00
Golgi-like, transneuronal retrograde labelling with CNS injections of herpes simplex virus type 1. Brain Res Bull (1989) 0.99
Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children. J Virol (1993) 0.99
Serum-neutralizing antibody to VP4 and VP7 proteins in infants following vaccination with WC3 bovine rotavirus. J Virol (1990) 0.98
Elevation of cyclic AMP in C-1300 murine neuroblastoma by adenosine and related compounds and the antagonism of this response by methylxanthines. Biochem Pharmacol (1977) 0.98
Varicella in hairless guinea pigs. J Infect Dis (1991) 0.98
Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: A double-blind, dose-ranging, placebo-controlled, multicenter trial. J Infect Dis (1999) 0.98
Clinical and immunologic evaluation of trimellitic anhydride-and phthalic anhydride-exposed workers using a questionnaire with comparative analysis of enzyme-linked immunosorbent and radioimmunoassay studies. J Allergy Clin Immunol (1982) 0.97
Diisocyanate conjugate and immunoassay characteristics influence detection of specific antibodies in HDI-exposed workers. Clin Exp Allergy (2007) 0.97
Protection of adults rechallenged with a human rotavirus. J Infect Dis (1990) 0.97
Heterogeneity of specific-IgE responses in workers sensitized to acid anhydride compounds. J Allergy Clin Immunol (1984) 0.97
Genital reinfection after recovery from initial genital infection with herpes simplex virus type 2 in guinea pigs. J Infect Dis (1986) 0.96
HSV-2 transmission. Antiviral Res (2004) 0.96
Thymidine kinase-deficient herpes simplex virus type 2 genital infection in guinea pigs. J Virol (1985) 0.96
Effect of undecylenic acid as a topical microbicide against genital herpes infection in mice and guinea pigs. Antiviral Res (1999) 0.96
Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines. US Rotavirus Vaccine Efficacy Group. Vaccine (1995) 0.95
Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs. J Infect Dis (2000) 0.95
Knowledge of gonorrhea in adolescent females with a history of STD. Clin Pediatr (Phila) (1994) 0.95
Antibody response to type-common and type-unique epitopes of herpes simplex virus polypeptides. J Med Virol (1985) 0.95
Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatr Infect Dis J (2000) 0.95
Attenuation of a human rotavirus vaccine candidate did not correlate with mutations in the NSP4 protein gene. J Virol (1997) 0.94
Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy. Antiviral Res (1989) 0.94
Herpesvirus latency and recurrence. Prog Med Virol (1986) 0.94
Quantity of latency-associated transcript produced by herpes simplex virus is not predictive of the frequency of experimental recurrent genital herpes. J Infect Dis (1994) 0.94
A temporal analysis of acyclovir inhibition of induced herpes simplex virus type 1 In vivo reactivation in the mouse trigeminal ganglia. J Infect Dis (1999) 0.93